French National Center for Scientific Research
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
Sumitomo Pharma’s stem cell therapy for Parkinson’s given limited approval in Japan
The company has been given manufacturing and marketing authorisation for the therapy
Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms
The platform will passively collect data to understand treatment responses in everyday life
Mission Therapeutics advances Parkinson’s disease candidate
The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK
PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s
The US-based company develops light-based therapies for neurodegenerative conditions
TRIMTECH Therapeutics establishes Scientific Advisory Board
Alessio Ciulli has been appointed as Chair of the board
Roche shares promising data from Alzheimer’s disease development portfolio
The company is planning to initiate phase 3 studies of trontinemab in early AD this year
UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis
It is hoped that the test could be available for widespread UK use in the coming years
GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn
The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform
Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review
Approximately 2.9 million people worldwide are living with the neurodegenerative disease
GSK to explore link between Shingrix and dementia risk in new UK research collaboration
More than 55 million people worldwide are currently living with the neurodegenerative disease
UK drug repurposing study identifies several potential dementia treatments
An estimated 982,000 people in the UK are currently living with the neurodegenerative disease